Fig. 2.

EPs® 7630 pretreatment modulates the cytokine production of activated lymphocytes. a, b Human PBMCs were pretreated with different concentrations of EPs® 7630 as indicated for 24 h. Afterwards, activators of T cells (anti-CD3/anti-CD28 Abs) (a) and innate lymphoid cells (cytokine mixture composed of IL-1β, IL-2, and IL-12) (b) were added for further 24 h. Quantification of IL-17, IL-22 and IFN-γ in culture supernatants was performed by ELISA. Data from 12 donors per group are given as mean ± SEM. Significant differences are indicated (*p < 0.05; **p < 0.01, Wilcoxon matched-pairs signed-rank test)